

QL

**PCT**

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/31, 1/21, C07K 14/22, 16/12, G01N 33/53, 33/569, A61K 31/70, 39/095, 39/40, 48/00</b>		<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 99/61620</b>								
			<b>(43) International Publication Date:</b> 2 December 1999 (02.12.99)								
<b>(21) International Application Number:</b> PCT/EP99/03603 <b>(22) International Filing Date:</b> 26 May 1999 (26.05.99) <b>(30) Priority Data:</b> 9811260.0 26 May 1998 (26.05.98) GB <b>(71) Applicant (for all designated States except US):</b> SMITHKLINE BEECHAM BIOLOGICALS S.A. [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> RUEELLE, Jean-Louis [BE/BE]; SmithKline Beecham Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE). <b>(74) Agent:</b> TYRRELL, Arthur, William, Russell; SmithKline Beecham, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>  <b>(88) Date of publication of the international search report:</b> 2 March 2000 (02.03.00)									
<b>(54) Title:</b> NEISSERIA MENINGITIDIS ANTIGENIC POLYPEPTIDES, CORRESPONDING POLYNUCLEOTIDES AND PROTECTIVE ANTIBODIES  <p style="text-align: center;">Protective effect of the anti-BASB030 antibodies in the passive protection model</p> <p style="text-align: center;"><u>Protection against infection</u></p> <table border="1"><caption>Protection against infection</caption><thead><tr><th>Groups</th><th>Log10 (CFU)</th></tr></thead><tbody><tr><td>PBS</td><td>~4.2</td></tr><tr><td>H44/29 mab</td><td>~3.2</td></tr><tr><td>Anti-BASB030 abs</td><td>~3.2</td></tr></tbody></table>				Groups	Log10 (CFU)	PBS	~4.2	H44/29 mab	~3.2	Anti-BASB030 abs	~3.2
Groups	Log10 (CFU)										
PBS	~4.2										
H44/29 mab	~3.2										
Anti-BASB030 abs	~3.2										
<b>(57) Abstract</b> <p>The invention provides <i>Neisseria meningitidis</i> BASB030 polypeptides and polynucleotides encoding BASB030 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are antibodies, diagnostic, prophylactic and therapeutic uses thereof.</p>											